Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2015-07-23 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science EN
Regulatory Filings Classification · 95% confidence The document is a press release dated July 23, 2015, announcing the successful non-futility test result for the drug masitinib in a Phase 3 clinical trial for multiple sclerosis. It details the study status, efficacy measures, and scientific rationale. Crucially, it also announces a future web conference to discuss these results, stating that the presentation supporting the conference call will be made available *upon completion of the web call*. Since the document itself is a detailed announcement of clinical trial progress and scientific data, and not merely a short notice stating a report is attached or published, it is best classified as an Investor Presentation (IP) or a detailed announcement of scientific/clinical progress. Given the depth of scientific and clinical detail, and the announcement of an upcoming presentation/discussion, 'Investor Presentation' (IP) is the most fitting category, as it conveys detailed strategic and scientific information to investors, even if the format here is a press release rather than a slide deck. It is not a standard regulatory filing (10-K, IR, ER) or a simple report announcement (RPA).
2015-07-23 English
AB Science EN
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science detailing that abstracts reporting updated data from three phase 2 clinical studies of masitinib in oncology have been accepted for presentation at the European Cancer Congress 2015. It provides details about the abstracts, presentation schedules, and includes commentary and references to previous press releases. This is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is a specific announcement regarding clinical trial data presentation, which falls under general investor/research communication. Since it is an announcement about clinical data being presented at a conference, and not a formal financial report, the closest fit among the provided options is 'Regulatory Filings' (RNS) as a general announcement category, or potentially 'Investor Presentation' (IP) if the content were structured as a presentation deck, but here it is a press release format announcing external presentation details. Given the nature of announcing clinical data acceptance for a conference, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it is highly specific scientific news. It is not a standard financial report or a management change announcement. I will classify it as RNS as it is a specific, non-standard announcement.
2015-07-07 English
AB Science FR
Regulatory Filings Classification · 95% confidence The document is a press release dated July 7, 2015, announcing that AB Science will present abstracts of Phase 1/2 clinical studies on masitinib for various cancers at the 2015 European Cancer Congress. The text details the specific abstracts, presentation dates, and provides commentary and references to previous press releases regarding study results. This is not a formal regulatory filing like a 10-K, an official earnings release (ER), or a comprehensive Interim Report (IR). It is an announcement about participation in a scientific conference and the presentation of study data, which aligns best with a general announcement or a specific type of investor communication. Since it is announcing the presentation of scientific data (abstracts) at a conference, it is most closely related to Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the context of presenting clinical trial data summaries, 'Investor Presentation' (IP) is a strong candidate, but since it is specifically an announcement *about* presentations at an external congress, and not the presentation slides themselves, 'Regulatory Filings' (RNS) serves as a suitable general category for corporate news releases that don't fit the highly specific financial/governance codes. However, the content is highly focused on clinical trial updates intended for investors and the scientific community. Comparing it to the definitions, it is an announcement of data being shared, similar to an IP, but the format is a press release. Given the options, and that it is a corporate announcement detailing scientific progress, 'Investor Presentation' (IP) captures the intent better than the generic 'RNS', although it is not the presentation itself. Since the document is a press release announcing the presentation of study abstracts, and not the presentation slides or a formal financial report, 'RNS' (Regulatory Filings - general regulatory announcements) is the most appropriate fallback for a corporate news release detailing scientific milestones, especially since 'IP' usually refers to the actual slide deck.
2015-07-07 French
AB Science FR
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled 'INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL' (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 221-1 point 2 f and 223-16 of the AMF General Regulation (Autorité des Marchés Financiers). It provides a table showing the total number of shares and voting rights as of a specific date (June 30, 2015). This content directly relates to reporting changes in share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, although it is a specific monthly disclosure. Given the options, SHA covers capital structure changes. However, since it is a mandatory monthly disclosure of voting rights, it is a specific type of regulatory filing. Reviewing the definitions, none perfectly match a 'Monthly Voting Rights Disclosure'. 'SHA' relates to capital changes, which this document details. 'MRQ' is for major shareholding notifications, which is different. 'RNS' is a general regulatory fallback. Since the core content is the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, SHA is the most appropriate fit among the provided specific codes, as it details the current capital composition.
2015-07-03 French
AB Science EN
Investor Presentation Classification · 95% confidence The document is a press release dated July 2, 2015, announcing that the Data and Safety Monitoring Board (DSMB) recommended the continuation of three Phase 2 clinical studies assessing the drug masitinib for various cancers. It details the objectives, patient populations, and background information on the drug and the company (AB Science SA). This type of announcement, detailing clinical trial progress, safety data review, and market potential, is characteristic of an Investor Presentation (IP) or a general press release related to R&D progress. Since it is a detailed update on clinical trials and market rationale, it fits best under Investor Presentation (IP) which often includes such strategic and clinical updates, rather than a brief Earnings Release (ER) or a formal regulatory filing like 10-K or IR. It is not a transcript (CT), a management discussion (MDA), or a formal financial report (IR/10-K).
2015-07-02 English
AB Science FR
Regulatory Filings Classification · 85% confidence The document is a press release dated July 2, 2015, from the pharmaceutical company AB Science SA. It announces that the Data and Safety Monitoring Board (DSMB) recommended continuing three Phase 2 clinical trials evaluating the drug masitinib for various cancers (liver, breast, head and neck). The text details the objectives, patient populations, and rationale for continuing the trials based on preliminary efficacy and tolerability data. This type of announcement, detailing clinical trial progress, regulatory/safety committee decisions, and providing background on the drug and company, is characteristic of an Earnings Release (ER) or a general corporate/investor update. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), it best fits the 'Earnings Release' category, as these often include operational updates alongside financial highlights, or, more broadly, a general corporate announcement. Given the focus on clinical trial progress and committee recommendations, it functions as a significant operational update often bundled with or replacing a standard ER in biotech/pharma. However, since it is not explicitly stating quarterly/periodical financial results (key highlights only), and is focused purely on R&D progress, it is a significant corporate announcement. In the absence of a specific 'Clinical Trial Update' code, and given its nature as a formal, dated announcement of material operational progress, it aligns most closely with the function of an Earnings Release (ER) which communicates key period performance/updates, or potentially a Regulatory Filing (RNS) if it were less structured. Given the structure and content (announcement of key operational milestones), ER is a strong candidate, but since it's not explicitly financial results, I will consider if it fits better elsewhere. It is not a presentation (IP), a factsheet (FS), or a management discussion (MDA). It is a formal announcement of a material event. In many databases, significant operational updates like this are classified under ER or RNS. Since it is a structured press release announcing a major operational milestone (DSMB recommendation), I will classify it as an Earnings Release (ER) as it serves to update the market on the company's progress, which is a core function of ERs outside of pure numbers, or RNS as a general regulatory announcement. Given the detailed nature of the update, it is more substantial than a simple RNS fallback. I will lean towards ER as it communicates the 'results' of the DSMB review, similar to how an ER communicates the 'results' of a quarter. However, if we strictly follow the definitions, it is an announcement of clinical progress, which often falls under RNS if not explicitly financial. Let's re-evaluate: It is a press release announcing a positive development in R&D. This is a common component of an ER, but the document itself is not titled as such. It is a general corporate communication. I will use RNS as the most appropriate general regulatory/corporate announcement category when specific operational codes are missing, as it is a formal communication to the market about a material event not covered by other specific codes like DIV, DIRS, or CAP. The document length (11k chars) confirms it is not a short RPA.
2015-07-02 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.